Transcode Therapeutics Inc（RNAZ）股票分析RNAZTranscode Therapeutics Inc

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Transcode Therapeutics Inc (RNAZ) is not a good buy right now due to its extremely low RSI of 6.667, indicating it is oversold, and a staggering year-to-date change of -70.54%, suggesting a significant decline in value. The forward P/E ratio is 0, indicating no expected earnings, and the stock has a current price of 2.18, which is far below its historical SMA of 7.604. The main risk is the negative net income, which reached -19,510,296 in Q1 2026, reflecting ongoing financial struggles.